Article Text

PDF
PTU-077 Increased Long-Term Cancer Risk in Autoimmune Hepatitis (AIH): Relation to Immunosuppressive Drug Treatment
  1. BS Hoeroldt1,2,
  2. D Gleeson1,
  3. K Shephard1,
  4. N Farquarson1,
  5. E MacFarlane1,
  6. M Karajeh1,
  7. J Poole2
  1. 1Hepatology, Sheffield Teaching Hospitals
  2. 2Cancer Registry for Yorkshire and the Humber, Cancer Registry, Sheffield, UK

Abstract

Introduction  

Background Increased rates of hepatocellular (HCC) and recently, of extra-hepatic cancer have been reported in Autoimmune Hepatitis (AIH). Increased cancer rates in inflammatory bowel disease and following organ transplant have been linked to immunosuppressive (IS) drug therapy; this association has not been assessed in AIH. Aim. Evaluation relationship of cancer risk to non-steroid IS therapy in AIH

Methods 241 patients (197 F, age at diagnosis (median (range) 56 (2.5–87 yr), presenting 1971–2007 with AIH (1999 International Group criteria) and followed for ≥6 months. Cancers (ICD-10 code starting with C) were captured by clinical record review and individually linked to data from the English National Cancer Registry. In cases of discrepancy, records were re-checked and a consensus decision made. Patients were censored at death, liver transplant, changed diagnosis to PBC, cessation of follow up, or on 1/1/2014. We excluded cancers diagnosed before or within 6 months of AIH diagnosis or >30 days after follow-up ceased. Standardised incidence ratios (SIR; first cancer only) were calculated, relative to age-gender adjusted UK population rates. For non-melanoma skin cancer (NMSC), we considered only the years 2000–13, as there was under-reporting of NMSC to the registry prior to this. We estimated (pre-cancer) duration and cumulative dose of azathioprine (received by 208 patients) and total duration of all (non-steroid only) IS drug therapy.

Results Follow up was 12 (0.5–43 yr): total 3134 patient-years. There was development of (a) HCC in 10 patients (all with cirrhosis): SIR (95% CI) 41 (20–75); (b) lympho-proliferative cancer in 6 patients: SIR 2.94 (1.08–6.4: (c) ≥1 NMSC in 15 patients (2000–13): SIR 2.95 (1.65–4.87). SIR for all other extra-hepatic cancers remained above unity: 1.51 (1.07–2.07). Using a competing risks regression model, age-adjusted all-cancer risk was associated with duration (Hazard ratio (HR) 1.10 (1.01–1.20) and with cumulative dose (HR 1.07 (1.00–1.15) of azathioprine and with total duration of non-steroid IS therapy (HR 1.07 (1.01–1.14). Compared to those receiving non-steroid IS for <0.25 yr, age-adjusted all-cancer HR was 2.54 (1.13–5.72) and 8.71 (3.55–21.4) in those receiving IS for 0.25–10 yr and for >10 yr respectively.

Conclusion Patients with AIH have increased risk of hepatic and extra-hepatic cancer, including lymphoproliferative and NMSC. This risk is associated with duration of non-steroid IS drug therapy.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.